Aethlon Medical Q1 FY27 net loss narrows 12.12% to $1.55 million

• Aethlon Medical posted a net loss attributable to common stockholders of $1.55 million, improving from $1.76 million a year earlier.
• Operating loss narrowed 11.9% to $1.58 million, on lower professional fees and reduced general and administrative costs.
• Cash and cash equivalents totaled $4.93 million at June 30, down from $5.03 million at March 31.
• Subsequent to quarter-end, it raised $4 million in gross proceeds via a public offering, funding operations for at least 12 months.
• Program update: first participant dosed in the third and final cohort of its Phase 1 oncology study in Australia; Long COVID manuscript accepted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608131615PR_NEWS_USPR_____LA25318) on August 13, 2026, and is solely responsible for the information contained therein.